Genmab-developed sclerosis treatment beats competition in small injector pen study

Following the approval of sclerosis drug Kesimpta, originally from Genmab, Novartis is positioning this drug against its competitors. New study shows patients' and health personnel's impression of the firm's special injector pen compared with treatments from Teva, Biogen and Merck.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

Novartis has, in a recent study, examined sclerosis patients' impressions of the firm's autoinjector pens used to administer its medication.

The recently approved drug Kesimpta has a high score in the survey.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs